Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years' follow-up

Molecular Urology

Volumn 3, Issue 3, 1999, Pages 287-293

  Goldenberg, S L ^a   Gleave, M E ^a   Taylor, D ^a   Bruchovsky, N ^a   Garnick, M ^a   Howell, S ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER GROWTH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SEXUAL FUNCTION; TREATMENT FAILURE;

EID: 0032738502     PISSN: 10915362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)